These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 25301733)

  • 1. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.
    Mak JP; Man WY; Ma HT; Poon RY
    Oncotarget; 2014 Nov; 5(21):10546-57. PubMed ID: 25301733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells.
    Mak JP; Man WY; Chow JP; Ma HT; Poon RY
    Oncotarget; 2015 Aug; 6(25):21074-84. PubMed ID: 26025928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
    Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
    Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
    Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
    Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
    Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
    Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors.
    Smith HL; Willmore E; Prendergast L; Curtin NJ
    Br J Cancer; 2024 Sep; 131(5):905-917. PubMed ID: 38965423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
    Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
    Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
    Aarts M; Sharpe R; Garcia-Murillas I; Gevensleben H; Hurd MS; Shumway SD; Toniatti C; Ashworth A; Turner NC
    Cancer Discov; 2012 Jun; 2(6):524-39. PubMed ID: 22628408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
    Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
    Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells.
    Qi W; Xie C; Li C; Caldwell JT; Edwards H; Taub JW; Wang Y; Lin H; Ge Y
    J Hematol Oncol; 2014 Aug; 7():53. PubMed ID: 25084614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
    Jin J; Fang H; Yang F; Ji W; Guan N; Sun Z; Shi Y; Zhou G; Guan X
    Neoplasia; 2018 May; 20(5):478-488. PubMed ID: 29605721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress.
    Saini P; Li Y; Dobbelstein M
    Oncotarget; 2015 May; 6(15):13072-87. PubMed ID: 25965828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
    Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
    Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
    [No Abstract]   [Full Text] [Related]  

  • 15. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
    Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ
    Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
    Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
    Jhuraney A; Woods NT; Wright G; Rix L; Kinose F; Kroeger JL; Remily-Wood E; Cress WD; Koomen JM; Brantley SG; Gray JE; Haura EB; Rix U; Monteiro AN
    Mol Cancer Ther; 2016 Jul; 15(7):1669-81. PubMed ID: 27196765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.
    Wang G; Niu X; Zhang W; Caldwell JT; Edwards H; Chen W; Taub JW; Zhao L; Ge Y
    Cancer Lett; 2015 Jan; 356(2 Pt B):656-68. PubMed ID: 25458954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma.
    Magnussen GI; Emilsen E; Giller Fleten K; Engesæter B; Nähse-Kumpf V; Fjær R; Slipicevic A; Flørenes VA
    BMC Cancer; 2015 Jun; 15():462. PubMed ID: 26054341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation.
    Restelli V; Vagni M; Arribas AJ; Bertoni F; Damia G; Carrassa L
    Br J Haematol; 2018 Apr; 181(1):129-133. PubMed ID: 28025833
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.